121 related articles for article (PubMed ID: 21406600)
1. Effect of cyclosporine on the pharmacokinetics of aliskiren in healthy subjects.
Rebello S; Compain S; Feng A; Hariry S; Dieterich HA; Jarugula V
J Clin Pharmacol; 2011 Nov; 51(11):1549-60. PubMed ID: 21406600
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of the oral direct renin inhibitor aliskiren in combination with digoxin, atorvastatin, and ketoconazole in healthy subjects: the role of P-glycoprotein in the disposition of aliskiren.
Vaidyanathan S; Camenisch G; Schuetz H; Reynolds C; Yeh CM; Bizot MN; Dieterich HA; Howard D; Dole WP
J Clin Pharmacol; 2008 Nov; 48(11):1323-38. PubMed ID: 18784280
[TBL] [Abstract][Full Text] [Related]
3. Itraconazole, a P-glycoprotein and CYP3A4 inhibitor, markedly raises the plasma concentrations and enhances the renin-inhibiting effect of aliskiren.
Tapaninen T; Backman JT; Kurkinen KJ; Neuvonen PJ; Niemi M
J Clin Pharmacol; 2011 Mar; 51(3):359-67. PubMed ID: 20400651
[TBL] [Abstract][Full Text] [Related]
4. Grapefruit juice greatly reduces the plasma concentrations of the OATP2B1 and CYP3A4 substrate aliskiren.
Tapaninen T; Neuvonen PJ; Niemi M
Clin Pharmacol Ther; 2010 Sep; 88(3):339-42. PubMed ID: 20664534
[TBL] [Abstract][Full Text] [Related]
5. Intestinal OATP1A2 inhibition as a potential mechanism for the effect of grapefruit juice on aliskiren pharmacokinetics in healthy subjects.
Rebello S; Zhao S; Hariry S; Dahlke M; Alexander N; Vapurcuyan A; Hanna I; Jarugula V
Eur J Clin Pharmacol; 2012 May; 68(5):697-708. PubMed ID: 22124880
[TBL] [Abstract][Full Text] [Related]
6. Effect of verapamil on the pharmacokinetics of aliskiren in healthy participants.
Rebello S; Leon S; Hariry S; Dahlke M; Jarugula V
J Clin Pharmacol; 2011 Feb; 51(2):218-28. PubMed ID: 20413453
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics, safety and tolerability of single and multiple oral doses of aliskiren in healthy Chinese subjects: a randomized, single-blind, parallel-group, placebo-controlled study.
Hu P; Bartlett M; Karan RS; Jiang J; Zhang S; Zhang J; Howard D; Yeh CM; Al-Fayoumi S; Jarugula V; Dole WP
Clin Drug Investig; 2010; 30(4):221-8. PubMed ID: 20192280
[TBL] [Abstract][Full Text] [Related]
8. The Effect of Single and Multiple Doses of Rifampin on the Pharmacokinetics of Doravirine in Healthy Subjects.
Yee KL; Khalilieh SG; Sanchez RI; Liu R; Anderson MS; Manthos H; Judge T; Brejda J; Butterton JR
Clin Drug Investig; 2017 Jul; 37(7):659-667. PubMed ID: 28353169
[TBL] [Abstract][Full Text] [Related]
9. A study of dose-proportionality in the pharmacokinetics of the oral direct renin inhibitor aliskiren in healthy subjects.
Limoges D; Dieterich HA; Yeh CM; Vaidyanathan S; Howard D; Dole WP
Int J Clin Pharmacol Ther; 2008 May; 46(5):252-8. PubMed ID: 18538111
[TBL] [Abstract][Full Text] [Related]
10. Potential for pharmacokinetic interactions between ambrisentan and cyclosporine.
Spence R; Mandagere A; Richards DB; Magee MH; Dufton C; Boinpally R
Clin Pharmacol Ther; 2010 Oct; 88(4):513-20. PubMed ID: 20811346
[TBL] [Abstract][Full Text] [Related]
11. Cyclosporine markedly raises the plasma concentrations of repaglinide.
Kajosaari LI; Niemi M; Neuvonen M; Laitila J; Neuvonen PJ; Backman JT
Clin Pharmacol Ther; 2005 Oct; 78(4):388-99. PubMed ID: 16198658
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics, safety, and tolerability of the novel oral direct renin inhibitor aliskiren in elderly healthy subjects.
Vaidyanathan S; Reynolds C; Yeh CM; Bizot MN; Dieterich HA; Howard D; Dole WP
J Clin Pharmacol; 2007 Apr; 47(4):453-60. PubMed ID: 17389554
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic interaction of the direct renin inhibitor aliskiren with furosemide and extended-release isosorbide-5-mononitrate in healthy subjects.
Vaidyanathan S; Bartlett M; Dieterich HA; Yeh CM; Antunes A; Howard D; Dole WP
Cardiovasc Ther; 2008; 26(4):238-46. PubMed ID: 19035874
[TBL] [Abstract][Full Text] [Related]
14. Aliskiren toxicity in juvenile rats is determined by ontogenic regulation of intestinal P-glycoprotein expression.
Hoffmann P; Beckman D; McLean LA; Yan JH
Toxicol Appl Pharmacol; 2014 Feb; 275(1):36-43. PubMed ID: 24388840
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of aliskiren in patients with end-stage renal disease undergoing haemodialysis.
Khadzhynov D; Slowinski T; Lieker I; Neumayer HH; Albrecht D; Streefkerk HJ; Rebello S; Peters H
Clin Pharmacokinet; 2012 Oct; 51(10):661-9. PubMed ID: 23018529
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of a three-way drug interaction between danoprevir, ritonavir and the organic anion transporting polypeptide (OATP) inhibitor ciclosporin.
Brennan BJ; Moreira SA; Morcos PN; Navarro MT; Asthappan J; Goelzer P; Weigl P; Smith PF
Clin Pharmacokinet; 2013 Sep; 52(9):805-13. PubMed ID: 23712757
[TBL] [Abstract][Full Text] [Related]
17. SLCO2B1 c.935G>A single nucleotide polymorphism has no effect on the pharmacokinetics of montelukast and aliskiren.
Tapaninen T; Karonen T; Backman JT; Neuvonen PJ; Niemi M
Pharmacogenet Genomics; 2013 Jan; 23(1):19-24. PubMed ID: 23151832
[TBL] [Abstract][Full Text] [Related]
18. Aliskiren exhibits similar pharmacokinetics in healthy volunteers and patients with type 2 diabetes mellitus.
Zhao C; Vaidyanathan S; Yeh CM; Maboudian M; Armin Dieterich H
Clin Pharmacokinet; 2006; 45(11):1125-34. PubMed ID: 17048976
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics, safety, and tolerability of the oral Renin inhibitor aliskiren in patients with hepatic impairment.
Vaidyanathan S; Warren V; Yeh C; Bizot MN; Dieterich HA; Dole WP
J Clin Pharmacol; 2007 Feb; 47(2):192-200. PubMed ID: 17244770
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of the oral direct renin inhibitor aliskiren alone and in combination with irbesartan in renal impairment.
Vaidyanathan S; Bigler H; Yeh C; Bizot MN; Dieterich HA; Howard D; Dole WP
Clin Pharmacokinet; 2007; 46(8):661-75. PubMed ID: 17655373
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
